Patient advocates decry CMS decision on Alzheimer’s drug coverage
By
Alicia Lasek
Feb 24, 2023
The Alzheimer’s Association and others have strongly criticized a decision by CMS to stand by its highly restrictive coverage for new dementia drugs.
On eve of Alzheimer’s drug decision, Congress critiques FDA for Aduhelm review failures
By
Alicia Lasek
Jan 03, 2023
An “atypical review process and corporate greed” factored into the FDA’s approval of Alzheimer’s drug Aduhelm in 2021, congressional investigators say. They recommend sticking to protocol...
Clinic reports no brain imaging abnormalities in patients given Aduhelm
By
Alicia Lasek
Oct 12, 2022
Brain scans showed no adverse side effects in patients treated with Aduhelm for Alzheimer’s disease, a neurology clinic study has found.
Lack of clinical use prompts Biogen to halt real-world Aduhelm drug trial
By
Alicia Lasek (f3)
Jun 28, 2022
The pharmaceutical firm Biogen has stopped a real-world clinical trial for its federally approved Alzheimer’s disease drug aducanumab (Aduhelm).
CMS restricts coverage of Alzheimer’s drug Aduhelm to clinical trials
By
Alicia Lasek
Apr 08, 2022
Coverage of aducanumab (Aduhelm) is officially limited to clinical trials only, the agency announced Thursday. Most stakeholders have called for restricted use while more efficacy and safety data is gathered,...
Clinical briefs for Tuesday, March 8
By
Alicia Lasek
Mar 08, 2022
Patients weigh risks of taking new Alzheimer’s drug Aduhelm … Palliative care services vary by U.S. region for these groups … The puzzling virus that affects almost everyone: Epstein-Barr …...
Clinical briefs for Friday, Feb. 18
By
Amy Novotney
Feb 18, 2022
CDC reforming COVID-19 guidance … Nearly three-quarters of the U.S. now estimated to be immune to omicron variant … Brain synapse destruction culprit behind Alzheimer’s cognitive decline … Treatment...
Biogen hit with class-action lawsuit involving Alzheimer’s drug Aduhelm
By
Alicia Lasek
Feb 10, 2022
The lawsuit alleges securities fraud on behalf of investors, adding to the ongoing fallout following Aduhelm’s controversial approval and Medicare’s questionable coverage proposal.
Clinical briefs for Wednesday, Feb. 9
By
Alicia Lasek
Feb 09, 2022
Higher pay not a cure-all for nurse retention, study shows … Majority of public support ongoing Aduhelm trials, would accept greater coverage costs, poll finds … 3G mobile network shutdown starts...
Tonko, LaHood urge HHS to expand access to Aduhelm, similar Alzheimer’s drugs
By
Alicia Lasek
Feb 08, 2022
The Medicare coverage proposal for these drugs is too restrictive, limiting potential benefits to a select few, the two congressmen argue in a letter sent Monday to HHS Secretary Xavier Becerra.